Bank of America Forecasts Strong Price Appreciation for Corteva (NYSE:CTVA) Stock

Corteva (NYSE:CTVA) had its price objective boosted by equities research analysts at Bank of America from $90.00 to $96.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price target would suggest a potential upside of 10.48% from the stock’s current price.

Other analysts have also recently issued reports about the company. UBS Group cut their target price on Corteva from $90.00 to $86.00 and set a “neutral” rating for the company in a research note on Tuesday, June 9th. The Goldman Sachs Group lifted their price target on shares of Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Berenberg Bank boosted their price target on shares of Corteva from $68.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, March 26th. Argus increased their price objective on shares of Corteva from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, CICC Research raised their price objective on shares of Corteva from $80.00 to $93.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $89.90.

Corteva Stock Up 0.1%

CTVA stock opened at $86.89 on Monday. Corteva has a twelve month low of $60.53 and a twelve month high of $88.21. The company has a market cap of $58.11 billion, a PE ratio of 51.11, a price-to-earnings-growth ratio of 2.65 and a beta of 0.56. The business’s 50-day simple moving average is $81.03 and its 200 day simple moving average is $78.54. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 EPS for the quarter, beating the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The firm had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. During the same quarter in the prior year, the firm posted $1.13 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, research analysts anticipate that Corteva will post 3.72 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Elevation Wealth Partners LLC grew its holdings in shares of Corteva by 334.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 339 shares of the company’s stock worth $29,000 after purchasing an additional 261 shares during the last quarter. JPL Wealth Management LLC acquired a new position in Corteva in the third quarter valued at about $25,000. Westfuller Advisors LLC boosted its position in Corteva by 2,764.3% in the first quarter. Westfuller Advisors LLC now owns 401 shares of the company’s stock valued at $34,000 after buying an additional 387 shares in the last quarter. Garton & Associates Financial Advisors LLC bought a new stake in Corteva during the fourth quarter worth about $27,000. Finally, Bank of Jackson Hole Trust acquired a new stake in shares of Corteva during the fourth quarter worth approximately $28,000. 81.54% of the stock is currently owned by institutional investors and hedge funds.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.